MedTrace Logo

Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT

NCT04338698 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 550

Last updated 2022-02-10

No results posted yet for this study

Summary

To evaluate the effectiveness of Hydroxychloroquine Sulfate (200 mg orally 8hr thrice a day for 5 days) vs oseltamivir (75 mg orally twice a day for 5 days) vs Azithromycin (500 mg orally daily on day 1, followed by 250 mg orally twice a day on days 2-5) alone and in combination (in all seven groups), in clearing the coronavirus nucleic acid from throat and nasal swab and in bringing about clinical improvement on day 7 of follow-up (primary outcomes).

Conditions

  • COVID 19

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine Sulfate (200 mg orally thrice a day for 5 days)

DRUG

Oseltamivir

Oseltamivir (75 mg orally twice a day for 5 days)

DRUG

Azithromycin

Azithromycin (500 mg orally once a day on day 1, followed by 250 mg orally daily on days 2-5)

Sponsors & Collaborators

  • Shehnoor Azhar

    lead OTHER

Principal Investigators

  • Javed Akram, FRCP · University of Health Sciences Lahore

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-22
Primary Completion
2020-11-15
Completion
2020-11-22

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04338698 on ClinicalTrials.gov